Pharmaceutical Executive

Pharmaceutical Executive Podcast
  • 0,0 (0)
  • BIOVIDENSKAB
  • TO GANGE OM UGEN

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

  1. Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products

    17 TIMER SIDEN

    Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products

    In today’s Pharmaceutical Executive Daily, AbbVie invests $380 million to expand API manufacturing capacity while Bora Pharmaceuticals and GSK enter a five-year manufacturing agreement, Novo Nordisk announces significant price reductions for its leading GLP-1 therapies, and Astellas enters a billion-dollar global collaboration with Vir Biotechnology to advance PSMA-targeting cancer treatments.

    2 min.
  2. Pharmaceutical Executive Daily: BioNTech Files Patent iInfringement Lawsuit Against Moderna

    4 DAGE SIDEN

    Pharmaceutical Executive Daily: BioNTech Files Patent iInfringement Lawsuit Against Moderna

    In today’s Pharmaceutical Executive Daily, BioNTech files a patent infringement lawsuit against Moderna, the Supreme Court rules against a large number of Trump-era tariffs, and the FDA approves a Calquence–venetoclax combination for certain blood cancers.

    2 min.
  3. Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals

    5 DAGE SIDEN

    Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals

    In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims & Hers enters a $1 billion agreement to acquire Eucalyptus, and experts examine how FDA can help ease early-stage clinical trial bottlenecks.

    2 min.
  4. Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine

    6 DAGE SIDEN

    Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine

    In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly signs a $100 million licensing agreement with CSL for an anti- IL-6 monoclonal antibody., and Southern Florida emerges as a growing biotech hub.

    2 min.
  5. Pharmaceutical Executive Daily: FDA Approves New Dosing Schedule for Rybrevant Faspro

    17. FEB.

    Pharmaceutical Executive Daily: FDA Approves New Dosing Schedule for Rybrevant Faspro

    In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary Robert F. Kennedy Jr. revises the agency’s leadership team, and industry expert Sandy Tammisetty discusses what it takes to deliver actual value in today’s pharmaceutical landscape.

    2 min.
  6. Pharmaceutical Executive Daily: Disc Medicine Receives CRL from FDA for Bitopertin

    16. FEB.

    Pharmaceutical Executive Daily: Disc Medicine Receives CRL from FDA for Bitopertin

    In today’s Pharmaceutical Executive Daily, the FDA issues a Complete Response Letter for Disc Medicine’s bitopertin in EPP, Edwards Lifesciences lifts its anti-copycat policy, and industry leaders examine how to scale global medical digital transformation while ensuring local fit.

    2 min.
  7. Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron

    13. FEB.

    Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron

    In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and a former AstraZeneca executive is charged with multiple offenses in China.

    1 min.
  8. Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna

    11. FEB.

    Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna

    In today’s Pharmaceutical Executive Daily, the FDA issues a refusal-to-file letter to Moderna for its seasonal influenza vaccine as the company secures a long-term agreement in Mexico, industry leaders assess China’s evolving role in global pharma strategy, and the FDA makes a decision on Keytruda in platinum-resistant ovarian cancer.

    2 min.
Se alle (294)

Om

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

Oplysninger

  • Skaber
    Pharmaceutical Executive Podcast
  • Aktive år
    2018 - 2026
  • Episoder
    294
  • Vurdering
    Ikke anstødeligt
  • Websted for serie
    Pharmaceutical Executive

Måske vil du også synes om